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Abstract
Objective
HIV-positive children, adolescents, and young adults are at increased risk poor musculo-
skeletal outcomes. Increased incidence of vitamin D deficiency in youth living with HIV may
further adversely affect musculoskeletal health. We investigated the impact of vitamin D
supplementation on a range of musculoskeletal outcomes among individuals aged 0–25
years living with HIV.
Methods
A systematic review was conducted using databases: PubMed/Medline, CINAHL, Web of
Knowledge, and EMBASE. Interventional randomised control trials, quasi-experimental tri-
als, and previous systematic reviews/meta-analyses were included. Outcomes included:
BMD, BMC, fracture incidence, muscle strength, linear growth (height-for-age Z-score
[HAZ]), and biochemical/endocrine biomarkers including bone turnover markers.
Results
Of 497 records, 20 studies met inclusion criteria. Thirteen studies were conducted in North
America, one in Asia, two in Europe, and four in Sub-Saharan Africa. High-dose vitamin D
supplementation regimens (1,000–7,000 IU/day) were successful in achieving serum 25-
hydroxyvitamin-D (25OHD) concentrations above study-defined thresholds. No improve-
ments were observed in BMD, BMC, or in muscle power, force and strength; however,
improvements in neuromuscular motor skills were demonstrated. HAZ was unaffected by
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low-dose (200–400 IU/day) supplementation. A single study found positive effects on HAZ
with high-dose supplementation (7,000 vs 4,000IU/day).
Conclusions
Measured bone outcomes were unaffected by high-dose vitamin D supplementation, even
when target 25OHD measurements were achieved. This may be due to: insufficient sample
size, follow-up, intermittent dosing, non-standardised definitions of vitamin D deficiency, or
heterogeneity of enrolment criteria pertaining to baseline vitamin D concentration. High-
dose vitamin D may improve HAZ and neuromuscular motor skills. Adequately powered tri-
als are needed in settings where HIV burden is greatest.
PROSPERO Number: CRD42016042938.
Introduction
The global scale-up of antiretroviral therapy (ART) has dramatically improved survival of
those living with HIV and converted what was once a life-threatening infection into a chronic,
treatable condition. HIV management now includes treatment of HIV infection, as well as
associated chronic comorbidities, for example increased risk of low bone mineral density
(BMD) [1–4]. Low BMD in youth living with HIV has been shown to far exceed those of HIV-
negative controls [3,5]. Similarly, multiple observational studies, in both high- and low-mid-
dle-income countries (LMIC), have demonstrated vitamin D insufficiency in HIV-positive
children, adolescents, and young adults [6–9], with a single study demonstrating increased
rates compared to HIV-negative age-matched controls [10].
During childhood and adolescent growth, bones grow in length, width and mineral content
until peak bone mass (PBM) is achieved [11]; PBM is a key determinant of future adult osteo-
porosis and lifetime fracture risk [12–14]. ‘Low bone mass’, defined as a dual energy X-ray
absorptiometry (DXA) measured BMD Z-score� -2 has been associated with low 25OHD
and altered vitamin D metabolism in HIV-positive youths [15,16]. Furthermore, HIV infection
increases bone turnover to reduce BMD even when vitamin D concentration is adequate [16].
HIV-associated alterations in vitamin D and bone metabolism are thought to arise from
inflammatory and metabolic properties of the HIV infection itself [17–20] and/or side effects
of ART [21–27] altering the molecular balance between bone formation and resorption. Intes-
tinal absorption, nutritional intake and/or sun exposure may also be reduced [28–31]. HIV
can cause delayed puberty [32,33] with associated reductions in bone mass [34–36] and
restricted linear growth [37]. Inadequate dietary vitamin D is associated with growth failure (i.
e. height-for-age Z-scores [HAZ]<-2) in HIV-positive children [38]. In sum, direct and indi-
rect effects of HIV on musculoskeletal health are multifactorial and are potentially exacerbated
by inadequate vitamin D.
Most current guidelines define vitamin D deficiency and insufficiency as a serum vitamin
D value (25OHD) <30 nmol/L (<12 ng/ml) and between 30–50 nmol/L respectively (12–20
ng/ml); however, consensus is lacking and defined thresholds vary between countries and spe-
cialty advisory committees [39–41]. Some experts advocate higher values (e.g>75 nmol/L
[>30 ng/ml]) in order to acieve maximal suppression of parathyroid hormone (PTH) and to
optimise bone matrix formation in light of altered vitamin D metabolism with HIV [42].
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Vitamin D supplementation has been shown to improve BMD in a range of paediatric
chronic diseases such as epilepsy [43], kidney disease [44] and juvenile idiopathic arthritis
[45], and to improve muscle function in HIV-negative adolescent girls [46]. Hence, it has been
hypothesised that the beneficial effects of vitamin D supplementation can be reproduced in
HIV infection.
Globally, there is an absence of evidence-based guidelines for vitamin D supplementation
in youth living with HIV. We aimed to systematically review the current evidence examining
the relationships between vitamin D supplementation and a range of musculoskeletal out-
comes in children, adolescents, and young adults living with HIV, to guide future strategies to
optimise musculoskeletal health.
Methods
Search strategy
Search strategy followed PRISMA guidance [47] (Fig 1). Articles were restricted to those pub-
lished in English and French from the year 2000–2017, reflecting the period of ART availabil-
ity. Articles were not restricted by geographic location. The following databases were searched:
PubMed/Medline, EMBASE, CINAHL, and Web of Knowledge, (S1–S4 Tables). A hand
search of the references cited for each retrieved article was performed. Furthermore, available
conference abstracts, within the past six years, were reviewed from: (i) the Conference on Ret-
roviruses and Opportunistic Infections, (ii) International AIDS Society, (iii) Infectious Dis-
eases Society of America ID Week, and (iv) the American Society for Bone and Mineral
Research.
Study selection
Interventional trials of oral or parenteral vitamin D with or without calcium were assessed,
including randomised control trials (RCT) and quasi-experimental studies (QET) (both con-
trolled and uncontrolled). Controlled QET consisted of pre- and post-intervention studies
with vitamin D and non-vitamin D arms, in addition to studies comparing high-dose and
standard-dosing regimens (standard-dose defined:�800 International Units [IU]/day).
Fig 1. PRISMA flow diagram of search results.
https://doi.org/10.1371/journal.pone.0207022.g001
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Uncontrolled QETs were considered if they utilised either a one group pre- post-intervention
design (vitamin D only) or an interrupted-time-series design [48]. Previous systematic reviews
were included. To ensure enough time to achieve outcomes, a minimum of six months follow-
up after enrolment was required for studies reporting radiological or clinical outcomes and
three months for those reporting biochemical/endocrine outcomes. Studies that had at least 10
individuals aged 1 month to 25 years, regardless of the mode of HIV acquisition and HIV
treatment status (ART naïve or experienced) were considered. Studies assessing bisphospho-
nates in conjunction with vitamin D supplementation were excluded.
Eligibility for inclusion was determined independently by two reviewers (JP & CR) using an
assessment toolkit with a pre-defined inclusion checklist [49,50].
Data extraction and quality assessment
Data were extracted independently using the Cochrane Public Health Group Data Extraction
and Assessment Form [50], with risk of bias (ROB) assessed using the Cochrane Handbook
for systematic reviews and reported independently as high, low, or unclear by both reviewers
(JP & CR) [49]. Data on study latitude/geographic location, participant age, gender, seasonal-
ity, adherence, dietary vitamin D intake (IU/day), skin colour/sun exposure and method of
25OHD and 1,25OHD quantification were recorded.
Biochemical/endocrine outcomes
Data were extracted for the biologically active variant and the stored form of vitamin D,
hydroxylated (1,25OHD) and non-hydroxylated (25OHD) vitamin D respectively, as well as:
endocrine/biochemical markers (calcium, phosphate, bone alkaline phosphatase [BAP], PTH,
and fibroblast growth factor [FGF]), serum and urine biomarkers of bone turnover (osteocal-
cin [OC], procollagen type-1 N-terminal propeptide [P1NP], collagen type-1 cross-linked C-
telopeptide [CTX], and N-terminal telopeptide [NTX]), and markers of systemic inflammation
(CRP, D-dimer, interleukins, tumour necrosis factors, and interferons).
Doses of vitamin D supplementation were standardised into daily doses (IU/day). Defini-
tions of vitamin D deficiency, insufficiency, and sufficiency were extracted for between-study
comparison (S5 Table).
Musculoskeletal outcomes (bone, muscle and linear growth)
BMC and BMD measured using the following radiographic techniques were acceptable: DXA,
computed tomography (including pQCT and high resolution pQCT), quantitative ultrasound
(measured by either speed of sound, broadband ultrasound attenuation, or stiffness index),
and/or digital X-ray radiogrammetry. For those not reporting BMD Z-scores, BMD measure-
ments were compared against standardised, age-matched paediatric Z-scores as outlined by
the International Society of Clinical Densitometry (ISCD) [51].
Studies assessing muscle function by measuring muscle strength, power, and/or force were
considered relevant, as were studies assessing muscle size and mass. Linear growth was
reported as HAZ, where SDs and standard error can be computed from Z-score values. HAZ
summary statistics by age/sex represent a comparison to WHO reference standards with an
expected mean HAZ of zero and SD of one. Z-scores were compared to the WHO Global
Database on Child Growth and Malnutrition standard classifications, if not reported by the
study authors [52]. Clinical outcomes of incident fractures and prevalent rickets and osteoma-
lacia were extracted.
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Adverse events
All adverse effects of vitamin D supplementation were recorded. Hypercalcemia, hypercal-
ciuria, renal calculi, and gastrointestinal upset were specifically screened for as these are recog-
nised complications of cholecalciferol supplementation in healthy populations [53].
Results
Study characteristics
A total of 607 articles were retrieved from database searches, a further 27 from hand searches
of references, and 7 conference abstracts. After removal of duplicates, 497 articles were
screened by title and abstract. The resulting 190 articles were then reviewed in full, of which 37
studies met inclusion criteria (Fig 1). The final 20 included studies were published between
2009–2017. Thirteen studies were conducted in North America (USA, Canada), two in Europe
(France, Italy), four in Sub-Saharan Africa (Botswana, South Africa, Uganda), and one pub-
lished conference abstract from Thailand. The follow-up time of the studies ranged from three
months to two years. All studies used oral Vitamin D3 (cholecalciferol) except the ongoing
Sudjaritruk et al. study which used D2 (ergocalciferol) for supplementation [54]. Four studies
supplemented calcium in conjunction with vitamin D [55,56,57,58] whereas three studies uti-
lised a multiple-micronutrient supplement which did not contain calcium [59,60,61]. There
was considerable dosing heterogeneity in regimens, ranging from 200–7,000 IU/day. Lower
dose regimens (200–400 IU/day) were used primarily in studies measuring HAZ, whereas
higher doses (1,000–7,000 IU/day) were used in those measuring biochemical/endocrine and
bone/muscle outcomes.
Studies are listed in Tables 1–4. Brown et al. [62] and Rovner et al. [63] published a second-
ary analyses of muscle and bone outcomes generated by Stallings et al. [64]. Arpadi et al.
(2012) published a follow-up study of the same population described by Arpadi et al. (2009),
but outcomes differed [55,56]. Havens et al. (2012b & 2014) published two secondary analyses
of data reported initially by Havens et al. (2012a) [65–67] and a third study assessing BMD in
conjunction with longitudinal biochemical data [68].
Study participants
Overall, the 20 trials included individuals aged six months to 25 years old. With the exception
of one Hepatitis C co-infected individual in the Foissac et al. [69] study, participants had no
concomitant acute and/or chronic disease, apart from HIV. There were no patients noted to
have concurrent TB. Mean CD4 count, when reported, varied between 587 [66] and 1041 [60],
and average CD4% from 27.8% [55] to 35.5% [70]. The majority of participants did not have
an AIDS-defining illness, except in the Botswanan trial published by Steenhoff et al., where
57% had CDC category C disease [71] and in the ongoing Thai trial where 50.3% had WHO
stage 3 or 4 disease [54]. The percentage of participants on ART was variable, ranging from 10
to 100%. In the study by Mda et al. those on ART were excluded altogether [59]. Low dietary
vitamin D intake among participants as compared to the Institute of Medicine (IOM) recom-
mended daily allowance (RDA) was ubiquitous across studies. Similarly, dietary calcium intake
was well below the RDA in the four studies to report this [56,57,64,72].
Study outcomes
The outcomes assessed can be broadly classified into four categories, with several studies
reporting primary outcomes in more than one of the following categories: 14 studies assessed
biochemical/endocrine parameters, most notably serum 25OHD concentration (Table 1), five
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Table 2. Characteristics of included studies assessing bone outcomes in response to cholecalciferol supplementation.
Study
author, year,
country
Study design Population
(n) and
gender6
Age1
range
and
mean
(SD)
Mode of HIV
acquisition
Intervention2
(mean daily VD
dose)3 (n)
Control (n) Baseline vitamin D
(nmol/L)4 levels and
exclusions
Summary of main
findings (25OHD
nmol/L)4,5
Arpadi et al.,
2012,
USA [56]
Double-Blind
RCT
59
M: 44.1%
6–16
years
100% perinatal 1. 100,000 IU
bimonthly7 +1g
Ca/day (= 1,667
IU/day) (n = 30)
Double placebo
(n = 29)
Baseline 25OHD in
VD+ = 62.2 (22.7)
• All intragroup bone
mass indices
increased over time
• No intergroup
difference in
TBBMC (p = 0.5),
TBBMD (p = 0.5),
LSBMC (p = 0.6),
LSBMD (p = 0.5) at
any time point
Stratified by
gender and age
VD
+10.2
(2.8)
VD-
11.0
(2.3)
25OHD <30 nmol/L
excluded (n = 5)
Participants on TDF
excluded
Eckard et al.,
2017
USA [77]
Double-Blind
RCT
102
M: 64%
8–25
years
20.3
(16.6–
22.8)8
53% perinatal 1. 60,000 IU
2. 120,000 IU
monthly (= 2,000
IUday
3. 4,000 IU/day)
(n = 36)8
18,000 IU
monthly (= 600
IU/day) (n = 66)
Baseline 25OHD for
all
participants = 42.4
(32.4–54.9)8
• Intragroup %
change LSBMD (p =
<0.001) % change
HBMD (p = 0.03),
and spine Z-scores
(p = 0.005) in VD
+ but only an
Intragroup change
in % HBMD
(p = 0.002) in VD-
• No intergroup
differences in %
change SBMD
(p = 0.3), % change
HBMD (0.37), spine
(p = 0.15) or hip Z-
score (p = 0.7)
• Combined (VD
+ and VD-)
intragroup
difference in %
change SBMD
(p<0.001) and spine
Z-score
Initially
stratified by EFV
use
Excluded if baseline
25OHD >75
Havens
et al., 2017
USA &
Puerto Rico
[57]
Double-Blind
RCT
214
M: 84%
16–24
years
22 (21–
23)8
Not defined
Median time
since HIV
diagnosis = 2
years
1. 50,000 IU
monthly + daily
multivitamin of
400 IU/day
+162mg Ca
(2,067 IU/day)
(n = 109)
Placebo
+ multivitamin of
400 IU/day + 162
mg Ca (n = 105)
Baseline 25OHD for
all
participants = 40.9
(28.5–59.7)8
• No intergroup
differences in
LSBMD
• No intragroup
difference in VD
+ or VD- for lumbar
LSBMD although
trend towards an
increase in the VD
+ group (+1.17%
[-0.75% to +2.74]
p<0.001)
• No change in
HBMD or TBBMD
Participants all
on TDF
containing ART
Participants
stratified by sex,
age, and race
No baseline 25OHD
exclusion criteria
(Continued)
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studies reported bone outcomes (Table 2), two studies described muscle function and structure
findings (Table 3), and four studies analysed HAZ (Table 4).
All studies, except Mda et al. [59], Chhagan et al. [61], and the abstract by Sudjaritruk et al.
[54] reported measures of potential harm and/or side-effects of the intervention although
none were powered for safety. No significant adverse events directly related to the intervention
were observed apart from two cases of renal calculi, although one was remote from the inter-
vention and the other part of the placebo group receiving only 400 IU/day of vitamin D.
Minor adverse events, when reported, consisted of transient hypercalcemia and
hypercalciuria.
Biochemical/endocrine outcomes. The majority of studies aimed to raise concentrations
of 25OHD>75 nmol/L with the goal of maximal PTH suppression (S5 Table). Kakalia et al.
demonstrated persistent hyperparathyroidism with serum 25OHD values between 50–75
nmol/L [73]. To achieve a measurement >75 nmol/L, higher supplementation doses (>1,000
Table 2. (Continued)
Study
author, year,
country
Study design Population
(n) and
gender6
Age1
range
and
mean
(SD)
Mode of HIV
acquisition
Intervention2
(mean daily VD
dose)3 (n)
Control (n) Baseline vitamin D
(nmol/L)4 levels and
exclusions
Summary of main
findings (25OHD
nmol/L)4,5
Rovner
et al., 2017
USA [63]
Double-Blind
RCT
58
M: 69%
5–24.9
years
20.9
(3.6)
35% perinatal 1. 7,000 IU/day
(n = 30)
Placebo (n = 28) Baseline 25OHD for
all
participants = 45.4
(21.2)
• No intra- or
intergroup
differences in
TBBMD, LSBMD,
TBBMC, or pQCT
tibia
Participants
stratified by age
and mode of
HIV acquisition
No baseline 25OHD
exclusion criteria
Preliminary Interim Data (from published abstract)
Sudjaritruk
et al. 2017
Thailand
[54]
Open-label
randomized trial
166
M: 48%
10–20
years
16.0
(14.4–
17.7)
100% perinatal
Median
duration of
ART 10 years
1. “high-dose”:
ergocalciferol/Ca
(3200IU/1.2 g
day)
“normal-dose”:
ergocalciferol/Ca
(400IU/1.2 g day)
Baseline 25OHD for
all
participants = 25.3
(20.7–33.2)
• Significant increases
over 48 weeks in
LSBMD Z-score in
both ‘high-dose’ and
‘normal dose’
groups with low-
BMD, but not
normal baseline
BMD.
• No between group
differences in
change in LSBMD
Analysis
stratified by
baseline Low-
BMD lumbar
spine Z-score
No baseline 25OHD
exclusion criteria
1. Mean/Median age based on group allocation and/or overall age when reported as such.
2. All oral cholecalciferol unless otherwise stated
3. Calculated based on 30 days/month.
4. Means (standard deviation) unless otherwise specified.
5. ng/ml transformed to nmol/L
6. Gender reported as percentage male
7. Bimonthly defined: once every 2 months.
8. Median (IQR) 8. 60,000 and 120,000 IU/month groups considered together in statistical analysis
25OHD = Serum 25-hydroxyvitamin D3 concentration; Ca = Calcium; EFV = Efavirenz; HBMD = Total Hip Bone Mineral Density;; LSBMC = Lumbar Spine Bone
Mineral Content; LSBMD = Lumbar Spine Bone Mineral Density; pQCT = peripheral quantitative computed tomography; RCT = Randomised Control Trial;
SBMC = Spinal Bone Mineral Content; SBMD = Spinal Bone Mineral Density; TBBMC = Total Body Bone Mineral Content TBBMD = Total Body Bone Mineral
Density; TDF = Tenofovir; VD+ = Vitamin D Intervention Arm; VD- = Control Arm
https://doi.org/10.1371/journal.pone.0207022.t002
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IU) than currently recommended were required; though it should be noted that other guide-
lines such as the Special Advisory Committee on Nutrition (SACN) [40], IOM [74], and Euro-
pean Food Safety Agency [75] guidlines are to achieve population mean levels above the
threshold not intended for clinical purposes. Higher mean and trough serum 25OHD values
were almost always achieved after supplementation [54,55,57,64,66,70–73,76,77]. Higher mean
monthly 25OHD values were seen with higher doses of cholecalciferol [55]. Lower baseline
values of 25OHD negatively impacted final serum 25OHD concentrations, and extended the
time needed to reach 25OHD>50 nmol/L and 75 nmol/L [66,69]. Without supplementation,
dietary intake of cholecalciferol, noted to be between 90–425 IU/day, was insufficient in
achieving 25OHD>75 nmol/L. Except for one study [73], responses in both 25OHD and
1,25OHD were equally seen [66,70,72], again with the most marked increase in those with the
lowest baseline 1,25OHD measurements [66].
Maximal physiologic PTH suppression, however, was inconsistently observed after chole-
calciferol supplementation. Whilst four studies demonstrated decreased serum PTH
[54,57,67,72], three did not, despite similar cholecalciferol dosing [64,73,77]. Decreased PTH
appeared to be in part dependent on participants’ exposure to tenofovir (TDF). Steenhoff et al.
demonstrated no intergroup difference in PTH between 4,000 and 7,000 IU/day, but without a
placebo group for comparison [71]. Although less frequently a reported outcome, changes in
serum calcium, phosphate and BAP concentrations were found to be largely unaffected after
Table 3. Characteristics of studies assessing muscle outcomes in response to cholecalciferol supplementation.
Study
author,
year,
country
Study design Population
(n) and
gender6
Age1
range
and
mean
(SD)
Mode of HIV
acquisition
Intervention2
(mean daily VD
dose)3 (n)
Control
(n)
Baseline vitamin D
(nmol/L)4 levels and
exclusions
Summary of main findings
(25OHD nmol/L)4,5
Brown
et al.,
2015,
USA [62]
Double-Blind
RCT
56
M: 67.9%
5–24.9
years
20.7(3.8)
34%
perinatal
66%
horizontal
7,000 IU/day
(n = 29)
Placebo
pill/liquid
(n = 27)
Baseline 25OHD for all
participants = 43.7
(21.1)
• No difference in jump power
[Watts] (p = 0.4), peak jump
energy [peak jump height in
cm/seconds to complete the
jump] (p = 0.14), muscular
forces (p = >0.4), muscular
strength (p = 0.9) VD+ vs.
VD-
• VD+ improved
neuromuscular motor skils vs.
VD- (p = 0.04)
VD
+ 20.0
(4.1)
VD- 21.4
(3.3)
2 participants from
parent study
excluded (Cerebral
Palsy)
Rovner
et al.,
2017
USA [63]
Double-Blind
RCT
58
M: 69%
5–24.9
years
20.9
(3.6)
35%
perinatal
7,000 IU/day
(n = 30)
Placebo
(n = 28)
Baseline 25OHD for all
participants = 45.4
(21.2)
• No intra- or intergroup
differences in muscle cross
sectional area
Participants
stratified by age
and mode of HIV
acquisition
No baseline 25OHD
exclusion criteria
1. Mean age based on group allocation and/or overall age when reported.
2. All oral cholecalciferol.
3. Calculated based on 30 days/month.
4. Means (standard deviation) unless otherwise specified.
5. ng/ml transformed to nmol/L
6. Gender reported as percentage male.
RCT = Randomised Control Trial; VD+ = Vitamin D Intervention Arm; VD- = Control Arm.
https://doi.org/10.1371/journal.pone.0207022.t003
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cholecalciferol supplementation [57,67,73]. Interestingly, in one study, changes in PTH and
BAP were only observed in the cholecalciferol supplemented group treated with TDF [67].
Changes in markers of bone remodelling (CTX, P1NP, OC) were not seen in two studies
where the treatment arm used doses of 2,000 IU/day or less [67,77] but when the treatment
dose was increased to 4,000 IU/day a decrease in CTX and P1NP was observed [77]. These
findings are similar to those found in the preliminary data by Sudjaritruk et al., however,
changes in bone turnover markers were demonstrated in both high- and standard-dose groups
without intergroup differences [54]. Increased FGF23 was reported in response to cholecalcif-
erol supplementation, although only in two studies, and increases were only observed in the
group receiving TDF-containing ART [57,78].
Musculoskeletal outcomes. In the five studies examining bone outcomes, no significant
differences in BMD nor BMC were noted between various high- and standard-doses of chole-
calciferol versus placebo, despite significant increases in 25OHD. Notably, as demonstrated by
Arpadi et al., 75% who received supplementation did not consistently maintain serum 25OHD
>75 nmol/L; 30% had at least one monthly serum 25OHD concentration <50 nmol/L [56].
Preliminary results of a 48-week randomised open-labelled trial assessing BMD after ‘high-
dose’ cholecalciferol (3,200 IU/day) versus ‘normal dose’ (400 IU/day), both groups also sup-
plemented with oral calcium, has recently been presented at the 9th International Workshop
on HIV paediatrics [54]. Analyses were stratified by the presence of low lumbar spine BMD Z-
score at baseline. BMD gains were seen in both ‘high-dose’ and ‘normal-dose’ groups who had
low-BMD at baseline. A weak trend was suggested towards greater BMD gains amongst the
‘high-dose’ group; however, full trial data are awaited. Body size adjustment was not consis-
tently considered, despite recommendations for size adjustment by the ISCD [79], which limits
the validity of bone outcomes.
In the one study focused on muscle outcomes, cholecalciferol supplementation did not
improve muscle power, force, or strength amongst youth undergoing jumping mechanogra-
phy, ankle and knee isometric/isokinetic testing and grip strength dynamometry, despite sub-
stantial cholecalciferol dosing (7,000 IU/day) which achieved significant increases in 25OHD
[62]. However, post-hoc multivariate analysis suggested participants with the greatest increases
in 25OHD tended to have greater jump power and energy, although it is unclear if this effect
was dependent on baseline 25OHD concentration. Interestingly, in one study, cholecalciferol
supplementation did have a beneficial effect on neuromuscular motor skills measured using
the Bruininks-Oseretsky Test of Motor Proficiency [80]. This included tests of fine motor pre-
cision and integration, dexterity, coordination, balance, and agility. Muscle cross-sectional
area was unaffected by cholecalciferol supplementation at the same daily dose in a separate
study [57].
Fig 2. Reviewer assessed risk of bias per Cochrane collaboration domain. High [red], unclear [yellow], and low
[green] {Source: created using Review Manager 5.3 [49]}. �Based on avaible data from published abstract, abstract oral
presentation, and clinical trials.gov protocol.
https://doi.org/10.1371/journal.pone.0207022.g002
Review: Vit. D supplementation & MSK health outcomes in children, adolescents, & young adults living with HIV
PLOS ONE | https://doi.org/10.1371/journal.pone.0207022 November 15, 2018 14 / 25
Three of four studies examining the effect of cholecalciferol on HAZ provided cholecalcif-
erol as part of a multi-micronutrient supplement and in much lower doses (200–400 IU/day)
than the aforementioned studies examining bone and muscle outcomes. No differences in
HAZ were observed after 6–18 months on these low-dose regimens [59–61]. Similarly, no dif-
ferences in HAZ were found in a separate study supplementing 4,000 IU/day to 30 individuals.
However, at a much higher dose (7,000 IU/day) this same study found significant differences
in HAZ after 12 weeks when compared with 4,000 IU/day [71]. There was again no placebo
group for comparison. Furthermore, 32% and 28% of participants, all HIV-positive, in studies
by Mda [59] and Steenhoff et al. [71] were reported as ‘already stunted’ (HAZ< -2) at baseline.
Those supplemented with cholecalciferol in studies by Ndeezi [60] and Chhagan et al. [61] also
had low mean HAZ at enrolment (HAZ -1.27, -0.9 respectively).
Risk of bias
The majority of studies were deemed of fair to good quality (Fig 2).
Discussion
In response to cholecalciferol supplementation, our review found no clear improvements in
BMD, BMC, or in muscle power, force or strength. High-dose cholecalciferol appeared to
show some effect on HAZ in a single study. The lack of effect on a broad range of musculoskel-
etal health outcomes may be due to differences in the definition of vitamin D deficiency used
as compared to those in place for the general population (S5 Table) and/or the application of
these definitions to the variable baseline 25OHD concentrations (Tables 1–4), which allowed
enrollment of individuals with 25OHD concentrations which could in some cases already be
deemed sufficient, prior to cholecalciferol supplementation.
The effect of cholecalciferol supplementation on biochemical/endocrine
outcomes
The majority of studies aimed to raise 25OHD concentrations >75 nmol/L, intending to
supress PTH, although more recent guidelines recommend lower 25OHD concentrations to
prevent poor musculoskeletal health in the general population [40,41]. The need for cholecal-
ciferol dosing above that recommended for HIV-negative individuals may be due to reduced
intestinal absorption and/or altered vitamin D metabolism, particularly in children and ado-
lescents [31,81]. The omission of those with very low baseline 25OHD biases results against
maximal effect; these children and adolescents would largely meet the criteria for rickets/osteo-
malacia and as such would be expected to benefit most from long-term supplementation.
Inclusion of individuals with vitamin D concentrations deemed adequate may have similarly
biased results. Alternatively, potentially even higher cholecalciferol doses and thresholds >75
nmol/L for 25OHD may be required. We identified submaximal PTH suppression in 3/7 stud-
ies, particularly when lower 25OHD thresholds were used or when 25OHD targets were incon-
sistently maintained, highlighting the importance of adherence and quality control
monitoring in studies. Overall, when assessing for normalisation of biochemical parameters,
the studies evaluated seem to favour higher 25OHD targets, e.g.�75 nmol/L.
The Endocrine Society Task Force clinical practice guideline remains one of few to contain
recommendations addressing vitamin D deficiency in children and young adults living with
HIV, although the evidence-base for these recommendations is limited [42]. Our findings do
not dispute their recommendation of a standardised maintenance daily dose of cholecalciferol
2–3 times that recommended for age, even in the absence of universal 25OHD screening. This
dose may be simplified to 1,500–2,000 IU/day for all paediatric patients, a recommendation
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which aligns with optimal dose modelling data by Foissac et al. [82]. Higher doses are likely to
be required for treatment of documented vitamin D deficiency, and if used, the full safety pro-
file should be substantiated under medical supervision. The Endocrine Society guideline sug-
gests treatment doses of 2,000 IU/day for infants and 4,000 IU/day for children 1–18 years old,
which should be accompanied by routine follow-up 25OHD measurements to ensure repletion
of biochemical stores. Expert consultation is advocated with higher dosing.
Unfortunately, PTH changes in response to cholecalciferol supplementation were variable.
In the five studies addressing bone outcomes, PTH was not measured, not reported, or when
reported failed to consistently normalise. Persistently elevated PTH may explain the lack of
improvement in BMD/BMC despite increases in 25OHD. Conflicting results in the context of
TDF treatment are reported where TDF, by lowering serum 25OHD concentrations, is associ-
ated with secondary hyperparathyroidism [83–85]. Havens et al. (2012b) observed a reduction
in PTH in those receiving TDF and cholecalciferol. Whilst, in those not receiving TDF, PTH
values were unchanged despite increased 25OHD, indicating a possible vitamin D indepen-
dent effect (67]. Dougherty et al. showed superior 25OHD responses whilst receiving efavirenz
(EFV), but without effects on PTH [72]. This finding contrasts with Eckard et al. who demon-
strated no differences in 25OHD in those receiving EFV [77]. Likewise, Havens et al. (2012a)
showed no PTH response from treatment with either TDF or EFV [66]. Potentially, different
ART regimens may influence musculoskeletal outcomes, independent of ARTs’ known
impacts on vitamin D metabolism [22,23,86].
Low 25OHD concentrations, with secondary hyperparathyroidism, increase bone turnover
(i.e. CTX, P1NP, OC); this is seen in young people with HIV just as it is the wider population
[7,87]. Surprisingly, Havens et al. (2012b) failed to corroborate this finding, even with normal-
isation of PTH in the TDF group [67]. Early treatment with cholecalciferol to prevent subclini-
cal hyperparathyroidism may moderate effects on bone turnover. However, this may require
high cholecalciferol dosing. Eckard et al. only demonstrated changes in CTX and P1NP with
4,000 IU/day (although no PTH response was seen) [77].
FGF23, an important regulator of phosphate homeostasis, is secreted by osteocytes in
response to 1,25OHD. FGF23 mediated phosphate regulation in HIV-associated vitamin D
deficiency remains poorly understood. TDF is associated with phosphaturia which may per-
petuate a hypothesised ‘functional vitamin D deficiency’, explained by higher concentrations
of vitamin D binding protein (VDBP) reducing free 1,25OHD [21]. Eckard et al. postulated a
compensatory decrease in VDBP with EFV after cholecalciferol supplementation [88]. Their
findings suggest that TDF and EFV may modify FGF23 response to vitamin D supplementa-
tion in adolescents living with HIV by altering vitamin D metabolism, at least in the short
term [65]. Further study is needed.
FGF23 increases in renal impairment [89–91], yet only three studies considered renal func-
tion in their analysis [67,77,78]. Others excluded patients with renal impairment altogether, or
inconsistently measured this at baseline. We further identified heterogeneity in 25OHD assays
with five different methods used.
The effect of cholecalciferol supplementation on musculoskeletal outcomes
The absence of any significant effect of cholecalciferol on BMD/BMC in the five retrieved stud-
ies may be a real finding or explained by a number of factors. (i) Intermittent dosing may
prove insufficient to sustain steady state 25OHD above essential thresholds. Daily, as opposed
to monthly/bi-monthly dosing, may be superior but must be balanced against adherence.
However, evidence pertaining to optimal dosing schedules remains contentious, particularly
as it relates to effects on bone mass, fractures, and falls [92,93] (ii) Arpadi et al.’s exclusion of
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individuals with the lowest 25OHD measurements may have biased results towards the null,
omitting participants who may benefit most from supplementation [56]. (iii) inclusion of indi-
viduals with adequate 25OHD concentrations across studies may have equally biased results
towards the null, similar to biochemical/endocrine outcomes. (iv) Reported intra-group
changes in BMD were not consistently analysed relative to age, changes in body composition
(Tanner Staging), and skeletal maturation (particularly height adjustments) [94,95]. Rovner
et al. [63] was the only study to explicitly state that such height adjustments were performed
whereas Arpadi et al. was the only study to report supplementary analyses of Tanner stage
advancement [56]. (v) DXA measurements are size-dependent, hence size correction is crucial,
otherwise low BMD/BMC may be explained by reduced height compared to a control popula-
tion, rather than an actual deficit on bone mass [79]. BMD must be interpreted relative to stat-
ure [96,97].
No paediatric studies from LMIC were available. Promisingly, preliminary results by Sud-
jaritruk et al. represents the first supplementation trial assessing BMD in youth living with
HIV outside of the USA; it will be important to see final BMD outcomes correctly size-adjusted
and so taking into account growth differences between groups [54]. Furthermore, published
data of concurrent changes in biochemical/endocrine markers will be valuable.
Our review highlights a lack of data on muscle size or functional outcomes following chole-
calciferol supplementation in HIV-positive youth. Although one study identified increases in
neuromuscular motor skills, no effects on muscle power, force or strength were found; perhaps
because only 33% achieved 25OH concentrations�80 nmol/l. Exploratory post-hoc analysis
suggested a responder effect such that participants with increased 25OHD after supplementa-
tion did show a positive response in jump power and energy [62]. These neuromuscular
improvements are important as poor motor function, evaluated by assessing muscular tone,
strength, and muscle volume, have been associated with HIV disease progression [98].
The only study to find an effect of cholecalciferol supplementation on HAZ used high-dose
supplementation (7,000 IU/day) and examined linear growth as a secondary outcome [71].
HAZ was the primary outcome in just one, much larger study, but of a much younger, heter-
ogenous population with high attrition rates secondary to death [61]. With the exception of
the Steenhoff et al. trial [71], concurrent 25OHD measurements were not evaluated making it
difficult to confirm the extent to which 25OHD concentrations improved after supplementa-
tion. In addition, high rates of baseline stunting may represent a missed opportunity, as ‘catch-
up’ growth may be unattainable even with adequate micronutrient supplementation. It
remains unclear at what age intervention may be beneficial. Follow-up time in all studies was
�18 months, likely insufficient to detect an effect on HAZ, particularly outside of the peri-
pubertal growth period. Lastly, studying cholecalciferol as part of a multi-micronutrient sup-
plement may mean effects are confounded by other micronutrients, supporting the need for
placebo controlled studies of high-dose vitamin D supplementation alone.
Summary of recommendations for future trials of vitamin D
supplementation in young people
Moving forward, studies in LMIC are of particular importance. Trials are needed to establish
the effect of vitamin D supplementation on musculoskeletal outcomes before PBM is achieved,
targeting the key pubertal stages of maximal growth velocity, when impact may be greatest.
Supplementation is needed to avoid secondary hyperparathyroidism which is the primary
stimulus for bone turnover [7,99]. Hence, concurrent PTH and 25OHD measurements (at
appropriate intervals relative to supplementation doses) are needed in studies measuring
BMD/BMC and linear growth. Future studies may also wish to investigate practical adjuncts,
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such as muscle strength training and weight bearing activity. Fracture incidence should be
reported in longitudinal studies, at least as a secondary outcome.
Optimal dosing regimens need to be established. Safety profiles need continued evaluation
especially at higher doses and for rare drug-related adverse events, missed by smaller studies.
Vitamin D should be supplemented at doses and in regimens that aim to provide sustained
25OHD above pre-defined thresholds. Consensus on threshold 25OHD concentrations defin-
ing vitamin D deficiency, insufficiency, and sufficiency would be welcome to standardise studies
and permit future meta-analyses. The majority of studies employ a 25OHD target of�75 nmol/
L as sufficient, with values 50–75 nmol/L considered insufficient and<50 nmol/L deficient. We
suggest future studies try not to exclude those with the lowest vitamin D concentrations. Whilst,
clinical trials where equipoise is lacking are unethical, for example in cases of symptomatic vita-
min D deficiency i.e. rickets, trials in asymptomatic youth who have incidental findings of low
25OHD concentrations which may simply reflect seasonality, can be justified. Where equipoise
is lacking, alternative study designs are more appropriate, such as longitudinal study designs
evaluating musculoskeletal outcomes before and after cholecalciferol replacement. Studies
should also address the long-term effects of supplementation in relation to baseline concentra-
tions, stratifying analysing according to adequacy of baseline 25OHD concentrations.
The combined effect of calcium and vitamin D supplementation on musculoskeletal out-
comes in youth living with HIV remains to be established. Future studies need to consistently
report and consider the effects of renal function, latitude, season, ethnicity, and local policies
on dietary fortification. Lastly, we recommend standardisation of both DXA measurements to
take account of size-adjustment as per the revised 2013 ISCD Pediatric Official Position
Guideline and the type of 25OHD assay used [79,100]. Use of alternative modalities in the
measurement of bone quality such as pQCT, high resolution pQCT and DXA measured tra-
becular bone score may prove beneficial and should be investigated in this population [101].
Limitations
Our analysis was limited by the four databases searched and to studies published in English
and French. Unfortunately, we were unable to perform a meta-analysis on the available data
given the heterogeneity in study designs and populations investigated. This heterogeneity
extended to a wide age and geographical range of study particpants, variablity in modes of
HIV infection and treatment, and a variety of cholecalciferol supplementation regimes which
limits identification of clear patterns in outcomes.
Conclusion
Our systematic review identified few, small studies, with heterogeneous study designs from
which we were unable to draw firm conclusions to guide future evidence-based vitamin D sup-
plementation strategies to optimise musculoskeletal health in youth living with HIV. However,
we were able to make a series of recommendations which we feel should be considered by all
researchers performing much needed further work in this field. Given the successful role out
of universal ART and the transition to HIV-associated chronic disease management, there is
an urgent need to identify any interventions that may attenuate the musculoskeletal conse-
quences of a lifetime of HIV infection and treatment.
Supporting information
S1 Table. Complete search strategy (PubMed/MEDLINE).
(PDF)
Review: Vit. D supplementation & MSK health outcomes in children, adolescents, & young adults living with HIV
PLOS ONE | https://doi.org/10.1371/journal.pone.0207022 November 15, 2018 18 / 25
S2 Table. Complete search strategy (EMBASE).
(PDF)
S3 Table. Complete search strategy (CINAHL).
(PDF)
S4 Table. Complete search strategy (Web of Knowledge).
(PDF)
S5 Table. Thresholds used to define vitamin D insufficiency, deficiency and excess in the
28 studies reviewed1, 2. 1.All values were transformed to nmol/L for standardisation purposes
2.All definitions utilise serum measurements of 25-hydroxyvitamin D3. (ND)Not defined.
(PDF)
S1 File. PRISMA 2009 checklist. From: Moher D, Liberati A, Tetzlaff J, Altman DG, The
PRISMA Group (2009). Preferred Reporting Items for Systematic Reviews and Meta-Analyses:
The PRISMA Statement. PLoS Med 6(7): e1000097. doi:10.1371/journal.pmed1000097.
(PDF)
Acknowledgments
We thank Suzanne Filteau (London School of Hygiene and Tropical Medicine) who provided
clarification regarding data pertaining to stunting in HIV-positive infants.
Author Contributions
Conceptualization: Justin Penner.
Data curation: Justin Penner.
Formal analysis: Justin Penner.
Funding acquisition: Rashida A. Ferrand.
Investigation: Justin Penner, Ceri Richards.
Methodology: Justin Penner, Rashida A. Ferrand, Celia L. Gregson.
Supervision: Rashida A. Ferrand, Celia L. Gregson.
Validation: Ceri Richards.
Visualization: James E. Burns.
Writing – original draft: Justin Penner, James E. Burns.
Writing – review & editing: Justin Penner, Rashida A. Ferrand, Ceri Richards, Kate A. Ward,
James E. Burns, Celia L. Gregson.
References
1. Warriner AH, Mugavero M, Overton ET. Bone alterations associated with HIV. Current HIV/AIDS
reports. 2014; 11(3):233–40. https://doi.org/10.1007/s11904-014-0216-x PMID: 25064454
2. Puthanakit T, Saksawad R, Bunupuradah T, Wittawatmongkol O, Chuanjaroen T, Ubolyam S, et al.
Prevalence and risk factors of low bone mineral density among perinatally HIV-infected Thai adoles-
cents receiving antiretroviral therapy. Journal of acquired immune deficiency syndromes (1999). 2012;
61(4):477–83.
3. DiMeglio LA, Wang J, Siberry GK, Miller TL, Geffner ME, Hazra R, et al. Bone mineral density in chil-
dren and adolescents with perinatal HIV infection. AIDS (London, England). 2013; 27(2):211–20.
Review: Vit. D supplementation & MSK health outcomes in children, adolescents, & young adults living with HIV
PLOS ONE | https://doi.org/10.1371/journal.pone.0207022 November 15, 2018 19 / 25
4. Schtscherbyna A, Pinheiro MF, Mendonca LM, Gouveia C, Luiz RR, Machado ES, et al. Factors asso-
ciated with low bone mineral density in a Brazilian cohort of vertically HIV-infected adolescents. Inter-
national journal of infectious diseases: IJID: official publication of the International Society for
Infectious Diseases. 2012; 16(12):e872–8.
5. Mora S, Zamproni I, Beccio S, Bianchi R, Giacomet V, Vigano A. Longitudinal changes of bone mineral
density and metabolism in antiretroviral-treated human immunodeficiency virus-infected children.
Journal of Clinical Endocrinology & Metabolism. 2004; 89(1):24–8.
6. Sudfeld CR, Duggan C, Aboud S, Kupka R, Manji KP, Kisenge R, et al. Vitamin D status is associated
with mortality, morbidity, and growth failure among a prospective cohort of HIV-infected and HIV-
exposed Tanzanian infants. The Journal of nutrition. 2015; 145(1):121–7. https://doi.org/10.3945/jn.
114.201566 PMID: 25527666
7. Sudjaritruk T, Bunupuradah T, Aurpibul L, Kosalaraksa P, Kurniati N, Prasitsuebsai W, et al. Hypovita-
minosis D and hyperparathyroidism: Effects on bone turnover and bone mineral density among perina-
tally HIV-infected adolescents. AIDS (London, England). 2016; 30(7):1059–67.
8. Atkinson Sea. Vitamin D deficiency in children with perinatally acquired HIV-1 infection living in th
eUK. 2nd joint Conference of BHIVA with BASHH: poster abstract P1592010.
9. Chokephaibulkit K, Saksawad R, Bunupuradah T, Rungmaitree S, Phongsamart W, Lapphra K, et al.
Prevalence of vitamin d deficiency among perinatally HIV-infected thai adolescents receiving antiretro-
viral therapy. Pediatric Infectious Disease Journal. 2013; 32(11):1237–9. https://doi.org/10.1097/INF.
0b013e31829e7a5c PMID: 24145954
10. Rutstein R, Downes A, Zemel B, Schall J, Stallings V. Vitamin D status in children and young adults
with perinatally acquired HIV infection. Clinical nutrition (Edinburgh, Scotland). 2011; 30(5):624–8.
11. Loud KJ, Gordon CM. Adolescent bone health. Archives of pediatrics & adolescent medicine. 2006;
160(10):1026–32.
12. Hernandez CJ, Beaupre GS, Carter DR. A theoretical analysis of the relative influences of peak BMD,
age-related bone loss and menopause on the development of osteoporosis. Osteoporosis interna-
tional: a journal established as result of cooperation between the European Foundation for Osteoporo-
sis and the National Osteoporosis Foundation of the USA. 2003; 14(10):843–7.
13. Zemel BS. Human biology at the interface of paediatrics: measuring bone mineral accretion during
childhood. Ann Hum Biol. 2012; 39(5):402–11. https://doi.org/10.3109/03014460.2012.704071 PMID:
22834897
14. Marshall D, Johnell O, Wedel H. Meta-analysis of how well measures of bone mineral density predict
occurrence of osteoporotic fractures. BMJ. 1996; 312(7041):1254–9. PMID: 8634613
15. Jacobson DL, Stephensen CB, Miller TL, Patel K, Chen JS, Van Dyke RB, et al. Associations of low
Vitamin D and elevated parathyroid hormone concentrations with bone mineral density in perinatally
HIV-infected children. Journal of Acquired Immune Deficiency Syndromes. 2017; 76(1):33–42. https://
doi.org/10.1097/QAI.0000000000001467 PMID: 28797019
16. Sudjaritruk T, Bunupuradah T, Aurpibul L, Kosalaraksa P, Kurniati N, Prasitsuebsai W, et al. Hypovita-
minosis D and hyperparathyroidism: effects on bone turnover and bone mineral density among perina-
tally HIV-infected adolescents. AIDS (London, England). 2016; 30(7):1059–67.
17. Fakruddin JM, Laurence J. HIV envelope gp120-mediated regulation of osteoclastogenesis via recep-
tor activator of nuclear factor kappa B ligand (RANKL) secretion and its modulation by certain HIV pro-
tease inhibitors through interferon-gamma/RANKL cross-talk. The Journal of biological chemistry.
2003; 278(48):48251–8. https://doi.org/10.1074/jbc.M304676200 PMID: 12975380
18. Fakruddin JM, Laurence J. HIV-1 Vpr enhances production of receptor of activated NF-kappaB ligand
(RANKL) via potentiation of glucocorticoid receptor activity. Archives of virology. 2005; 150(1):67–78.
https://doi.org/10.1007/s00705-004-0395-7 PMID: 15449141
19. Cotter EJ, Malizia AP, Chew N, Powderly WG, Doran PP. HIV proteins regulate bone marker secretion
and transcription factor activity in cultured human osteoblasts with consequent potential implications
for osteoblast function and development. AIDS research and human retroviruses. 2007; 23(12):1521–
30. https://doi.org/10.1089/aid.2007.0112 PMID: 18160010
20. Gazzola L, Bellistri GM, Tincati C, Ierardi V, Savoldi A, Del Sole A, et al. Association between periph-
eral T-Lymphocyte activation and impaired bone mineral density in HIV-infected patients. Journal of
translational medicine. 2013; 11:51. https://doi.org/10.1186/1479-5876-11-51 PMID: 23448662
21. Havens PL, Kiser JJ, Stephensen CB, Hazra R, Flynn PM, Wilson CM, et al. Association of higher
plasma vitamin D binding protein and lower free calcitriol levels with tenofovir disoproxil fumarate use
and plasma and intracellular tenofovir pharmacokinetics: cause of a functional vitamin D deficiency?
Antimicrobial agents and chemotherapy. 2013; 57(11):5619–28. https://doi.org/10.1128/AAC.01096-
13 PMID: 24002093
Review: Vit. D supplementation & MSK health outcomes in children, adolescents, & young adults living with HIV
PLOS ONE | https://doi.org/10.1371/journal.pone.0207022 November 15, 2018 20 / 25
22. Hariparsad N, Nallani SC, Sane RS, Buckley DJ, Buckley AR, Desai PB. Induction of CYP3A4 by efa-
virenz in primary human hepatocytes: comparison with rifampin and phenobarbital. Journal of clinical
pharmacology. 2004; 44(11):1273–81. https://doi.org/10.1177/0091270004269142 PMID: 15496645
23. Brown TT, McComsey GA. Association between initiation of antiretroviral therapy with efavirenz and
decreases in 25-hydroxyvitamin D. Antiviral therapy. 2010; 15(3):425–9. https://doi.org/10.3851/
IMP1502 PMID: 20516561
24. Orkin C, Wohl DA, Williams A, Deckx H. Vitamin D deficiency in HIV: a shadow on long-term manage-
ment? AIDS reviews. 2014; 16(2):59–74. PMID: 24759452
25. Cozzolino M, Vidal M, Arcidiacono MV, Tebas P, Yarasheski KE, Dusso AS. HIV-protease inhibitors
impair vitamin D bioactivation to 1,25-dihydroxyvitamin D. AIDS (London, England). 2003; 17(4):513–
20.
26. Ellfolk M, Norlin M, Gyllensten K, Wikvall K. Regulation of human vitamin D(3) 25-hydroxylases in der-
mal fibroblasts and prostate cancer LNCaP cells. Mol Pharmacol. 2009; 75(6):1392–9. https://doi.org/
10.1124/mol.108.053660 PMID: 19286836
27. Norlin M, Lundqvist J, Ellfolk M, Hellstrom Pigg M, Gustafsson J, Wikvall K. Drug-Mediated Gene Reg-
ulation of Vitamin D3 Metabolism in Primary Human Dermal Fibroblasts. Basic & clinical pharmacology
& toxicology. 2017; 120(1):59–63.
28. Coussens AK, Naude CE, Goliath R, Chaplin G, Wilkinson RJ, Jablonski NG. High-dose vitamin D-3
reduces deficiency caused by low UVB exposure and limits HIV-1 replication in urban Southern Afri-
cans. Proceedings of the National Academy of Sciences of the United States of America. 2015; 112
(26):8052–7. https://doi.org/10.1073/pnas.1500909112 PMID: 26080414
29. Etminani-Esfahani M, Khalili H, Soleimani N, Jafari S, Abdollahi A, Khazaeipour Z, et al. Serum vitamin
D concentration and potential risk factors for its deficiency in HIV positive individuals. Current HIV
research. 2012; 10(2):165–70. PMID: 22329521
30. Isaac R, Paul B, Geethanajali FS, Kang G, Wanke C. Role of intestinal dysfunction in the nutritional
compromise seen in human immunodeficiency virus-infected adults in rural India. Tropical doctor.
2017; 47(1):44–8. https://doi.org/10.1177/0049475515626338 PMID: 26809467
31. Carroccio A, Fontana M, Spagnuolo MI, Zuin G, Montalto G, Canani RB, et al. Pancreatic dysfunction
and its association with fat malabsorption in HIV infected children. Gut. 1998; 43(4):558–63. PMID:
9824586
32. Mothi SN, Swamy VH, Lala MM, Karpagam S, Gangakhedkar RR. Adolescents living with HIV in India
—the clock is ticking. Indian journal of pediatrics. 2012; 79(12):1642–7. https://doi.org/10.1007/
s12098-012-0902-x PMID: 23150229
33. Williams PL, Abzug MJ, Jacobson DL, Wang J, Van Dyke RB, Hazra R, et al. Pubertal onset in children
with perinatal HIV infection in the era of combination antiretroviral treatment. AIDS (London, England).
2013; 27(12):1959–70.
34. Chevalley T, Bonjour JP, Ferrari S, Rizzoli R. Deleterious effect of late menarche on distal tibia micro-
structure in healthy 20-year-old and premenopausal middle-aged women. Journal of bone and mineral
research: the official journal of the American Society for Bone and Mineral Research. 2009; 24
(1):144–52.
35. Finkelstein JS, Klibanski A, Neer RM. A longitudinal evaluation of bone mineral density in adult men
with histories of delayed puberty. The Journal of clinical endocrinology and metabolism. 1996; 81
(3):1152–5. https://doi.org/10.1210/jcem.81.3.8772591 PMID: 8772591
36. de Martino M, Tovo PA, Galli L, Gabiano C, Chiarelli F, Zappa M, et al. Puberty in perinatal HIV-1 infec-
tion: a multicentre longitudinal study of 212 children. Aids. 2001; 15(12):1527–34. PMID: 11504985
37. Majaliwa ES, Mohn A, Chiarelli F. Growth and puberty in children with HIV infection. Journal of endo-
crinological investigation. 2009; 32(1):85–90. https://doi.org/10.1007/BF03345686 PMID: 19337023
38. Modlin CE, Naburi H, Hendricks KM, Lyatuu G, Kimaro J, Adams LV, et al. Nutritional Deficiencies and
Food Insecurity Among HIV-infected Children in Tanzania. International journal of MCH and AIDS.
2014; 2(2):220–8. PMID: 27621976
39. Aspray TJ, Bowring C, Fraser W, Gittoes N, Javaid MK, Macdonald H, et al. National Osteoporosis
Society vitamin D guideline summary. Age and ageing. 2014; 43(5):592–5. https://doi.org/10.1093/
ageing/afu093 PMID: 25074538
40. Special Advisory Committee On Nutrition. Vitamin D and Health UK: 2016.
41. Ross AC, Manson JE, Abrams SA, Aloia JF, Brannon PM, Clinton SK, et al. The 2011 report on dietary
reference intakes for calcium and vitamin D from the Institute of Medicine: what clinicians need to
know. The Journal of clinical endocrinology and metabolism. 2011; 96(1):53–8. https://doi.org/10.
1210/jc.2010-2704 PMID: 21118827
Review: Vit. D supplementation & MSK health outcomes in children, adolescents, & young adults living with HIV
PLOS ONE | https://doi.org/10.1371/journal.pone.0207022 November 15, 2018 21 / 25
42. Holick MF, Binkley NC, Bischoff-Ferrari HA, Gordon CM, Hanley DA, Heaney RP, et al. Evaluation,
treatment, and prevention of vitamin D deficiency: An endocrine society clinical practice guideline.
Journal of Clinical Endocrinology and Metabolism. 2011; 96(7):1911–30. https://doi.org/10.1210/jc.
2011-0385 PMID: 21646368
43. Jekovec-Vrhovsek M, Kocijancic A, Prezelj J. Effect of vitamin D and calcium on bone mineral density
in children with CP and epilepsy in full-time care. Developmental medicine and child neurology. 2000;
42(6):403–5. PMID: 10875526
44. Bak M, Serdaroglu E, Guclu R. Prophylactic calcium and vitamin D treatments in steroid-treated chil-
dren with nephrotic syndrome. Pediatric nephrology (Berlin, Germany). 2006; 21(3):350–4.
45. Lovell DJ, Glass D, Ranz J, Kramer S, Huang B, Sierra RI, et al. A randomized controlled trial of cal-
cium supplementation to increase bone mineral density in children with juvenile rheumatoid arthritis.
Arthritis Rheum. 2006; 54(7):2235–42. https://doi.org/10.1002/art.21956 PMID: 16802360
46. Ward KA, Das G, Roberts SA, Berry JL, Adams JE, Rawer R, et al. A randomized, controlled trial of
vitamin D supplementation upon musculoskeletal health in postmenarchal females. The Journal of
clinical endocrinology and metabolism. 2010; 95(10):4643–51. https://doi.org/10.1210/jc.2009-2725
PMID: 20631020
47. Liberati A, Altman DG, Tetzlaff J, Mulrow C, Gotzsche PC, Ioannidis JP, et al. The PRISMA statement
for reporting systematic reviews and meta-analyses of studies that evaluate healthcare interventions:
explanation and elaboration. BMJ (Clinical research ed). 2009; 339:b2700.
48. Shadish W, Cook T., Campbell D., Experimental and Quasi-experimental designs for generalized
casual inference: Houghton Mifflin 2002.
49. The Cochrane Collaboration. Review Manager 5.3. 2016.
50. The Cochrane Public Health Group. Data Extraction and Assessment Template 2011.
51. Skeletal health Assessment In Children from Infancy to Adolescence [Internet]. 2013. http://www.iscd.
org/official-positions/2013-iscd-official-positions-pediatric/.
52. Onis M BM. WHO Global Database on Child Growth and Malnutrition Geneva: 1997.
53. Gallagher JC, Smith LM, Yalamanchili V. Incidence of hypercalciuria and hypercalcemia during vita-
min D and calcium supplementation in older women. Menopause (New York, NY). 2014; 21(11):1173–
80.
54. Sudjaritruk T, Aurpibul L, Bunupuradah T, Kanjanavanit S, Chotecharoentanan T, Taejaroenkul S,
et al. Impacts of vitamin D and calcium supplementation on bone mineral density among perinatally
HIV-infected adolescents: a 48-week randomized clinical trial. Journal of the International AIDS Soci-
ety. 2017; 20:8–9.
55. Arpadi SM, McMahon D, Abrams EJ, Bamji M, Purswani M, Engelson ES, et al. Effect of bimonthly
supplementation with oral cholecalciferol on serum 25-hydroxyvitamin D concentrations in HIV-
infected children and adolescents. Pediatrics. 2009; 123(1):e121–6. https://doi.org/10.1542/peds.
2008-0176 PMID: 19117833
56. Arpadi SM, McMahon DJ, Abrams EJ, Bamji M, Purswani M, Engelson ES, et al. Effect of supplemen-
tation with cholecalciferol and calcium on 2-y bone mass accrual in HIV-infected children and adoles-
cents: a randomized clinical trial. The American journal of clinical nutrition. 2012; 95(3):678–85.
https://doi.org/10.3945/ajcn.111.024786 PMID: 22258265
57. Havens PL, Stephensen CB, Van Loan MD, Schuster GU, Woodhouse LR, Flynn PM, et al. Vitamin
D3 Supplementation Increases Spine Bone Mineral Density in Adolescents and Young Adults with
HIV Infection Being Treated with Tenofovir Disoproxil Fumarate: A Randomized, Placebo-Controlled
Trial. Clinical infectious diseases: an official publication of the Infectious Diseases Society of America.
2017.
58. Sudjaritruk T, Bunupuradah T, Aurpibul L, Kosalaraksa P, Kurniati N, Prasitsuebsai W, et al. Hypovita-
minosis D and hyperparathyroidism: effects on bone turnover and bone mineral density among perina-
tally HIV-infected adolescents. AIDS (London, England). 2016; 30(7):1059–67.
59. Mda S, van Raaij JMA, MacIntyre UE, de Villiers FPR, Kok FJ. Improved appetite after multi-micronu-
trient supplementation for six months in HIV-infected South African children. Appetite. 2010; 54
(1):150–5. https://doi.org/10.1016/j.appet.2009.09.021 PMID: 19815042
60. Ndeezi G, Tylleskar T, Ndugwa CM, Tumwine JK. Effect of multiple micronutrient supplementation on
survival of HIV-infected children in Uganda: a randomized, controlled trial. Journal of the International
AIDS Society. 2010; 13:18. https://doi.org/10.1186/1758-2652-13-18 PMID: 20525230
61. Chhagan MK, Van den Broeck J, Luabeya KK, Mpontshane N, Tomkins A, Bennish ML. Effect on lon-
gitudinal growth and anemia of zinc or multiple micronutrients added to vitamin A: a randomized con-
trolled trial in children aged 6–24 months. BMC public health. 2010; 10:145. https://doi.org/10.1186/
1471-2458-10-145 PMID: 20298571
Review: Vit. D supplementation & MSK health outcomes in children, adolescents, & young adults living with HIV
PLOS ONE | https://doi.org/10.1371/journal.pone.0207022 November 15, 2018 22 / 25
62. Brown JC, Schall JI, Rutstein RM, Leonard MB, Zemel BS, Stallings VA. The impact of vitamin D3 sup-
plementation on muscle function among HIV-infected children and young adults: a randomized con-
trolled trial. Journal of musculoskeletal & neuronal interactions. 2015; 15(2):145–53.
63. Rovner AJ, Stallings VA, Rutstein R, Schall JI, Leonard MB, Zemel BS. Effect of high-dose cholecalcif-
erol (vitamin D-3) on bone and body composition in children and young adults with HIV infection: a ran-
domized, double-blind, placebo-controlled trial. Osteoporosis International. 2017; 28(1):201–9. https://
doi.org/10.1007/s00198-016-3826-x PMID: 27837268
64. Stallings VA, Schall JI, Hediger ML, Zemel BS, Tuluc F, Dougherty KA, et al. High-dose Vitamin D-3
Supplementation in Children and Young Adults with HIV A Randomized, Placebo-controlled Trial.
Pediatric Infectious Disease Journal. 2015; 34(2):E32–E40. https://doi.org/10.1097/INF.
0000000000000483 PMID: 24988118
65. Havens PL, Hazra R, Stephensen CB, Kiser JJ, Flynn PM, Wilson CM, et al. Vitamin D3 supplementa-
tion increases fibroblast growth factor-23 in HIV-infected youths treated with tenofovir disoproxil fuma-
rate. Antiviral therapy. 2014; 19(6):613–8. https://doi.org/10.3851/IMP2755 PMID: 24535626
66. Havens PL, Mulligan K, Hazra R, Flynn P, Rutledge B, Van Loan MD, et al. Serum 25-hydroxyvitamin
D response to vitamin D3 supplementation 50,000 IU monthly in youth with HIV-1 infection. The Jour-
nal of clinical endocrinology and metabolism. 2012; 97(11):4004–13. https://doi.org/10.1210/jc.2012-
2600 PMID: 22933542
67. Havens PL, Stephensen CB, Hazra R, Flynn PM, Wilson CM, Rutledge B, et al. Vitamin D3 decreases
parathyroid hormone in HIV-infected youth being treated with tenofovir: a randomized, placebo-con-
trolled trial. Clinical infectious diseases: an official publication of the Infectious Diseases Society of
America. 2012; 54(7):1013–25.
68. Havens PL, Stephensen CB, Van Loan MD, Schuster GU, Woodhouse LR, Flynn PM, et al. Decline in
bone mass with tenofovir disoproxil fumarate/emtricitabine is associated with hormonal changes in the
absence of renal impairment when used by HIV-uninfected adolescent boys and young men for HIV
preexposure prophylaxis. Clinical Infectious Diseases. 2017; 64(3):317–25. https://doi.org/10.1093/
cid/ciw765 PMID: 28013265
69. Foissac F, Meyzer C, Frange P, Chappuy H, Benaboud S, Bouazza N, et al. Determination of optimal
vitamin D3 dosing regimens in HIV-infected paediatric patients using a population pharmacokinetic
approach. British journal of clinical pharmacology. 2014; 78(5):1113–21. https://doi.org/10.1111/bcp.
12433 PMID: 24902982
70. Giacomet V, Vigano A, Manfredini V, Cerini C, Bedogni G, Mora S, et al. Cholecalciferol supplementa-
tion in HIV-infected youth with vitamin D insufficiency: effects on vitamin D status and T-cell pheno-
type: a randomized controlled trial. HIV clinical trials. 2013; 14(2):51–60. https://doi.org/10.1310/
hct1402-51 PMID: 23611825
71. Steenhoff AP, Schall JI, Samuel J, Seme B, Marape M, Ratshaa B, et al. Vitamin D(3)supplementation
in Batswana children and adults with HIV: a pilot double blind randomized controlled trial. PloS one.
2015; 10(2):e0117123. https://doi.org/10.1371/journal.pone.0117123 PMID: 25706751
72. Dougherty KA, Schall JI, Zemel BS, Tuluc F, Hou X, Rutstein RM, et al. Safety and Efficacy of High-
Dose Daily Vitamin D3 Supplementation in Children and Young Adults Infected With Human Immuno-
deficiency Virus. Journal of the Pediatric Infectious Diseases Society. 2014; 3(4):294–303. https://doi.
org/10.1093/jpids/piu012 PMID: 26625449
73. Kakalia S, Sochett EB, Stephens D, Assor E, Read SE, Bitnun A. Vitamin D supplementation and CD4
count in children infected with human immunodeficiency virus. Journal of Pediatrics. 2011; 159
(6):951–7. https://doi.org/10.1016/j.jpeds.2011.06.010 PMID: 21820130
74. Institute of Medicine Committee to Review Dietary Reference Intakes for Vitamin D, Calcium. The
National Academies Collection: Reports funded by National Institutes of Health. In: Ross AC, Taylor
CL, Yaktine AL, Del Valle HB, editors. Dietary Reference Intakes for Calcium and Vitamin D. Washing-
ton (DC): National Academies Press (US) National Academy of Sciences.; 2011.
75. European Food Safety Agency. Scientific Opinion on Dietary Reference Values for Vitamin D. EFSA
Journal 2016.
76. Poowuttikul P, Thomas R, Hart B, Secord E. Vitamin D insufficiency/deficiency in HIV-infected inner
city youth. Journal of the International Association of Providers of AIDS Care. 2014; 13(5):438–42.
https://doi.org/10.1177/2325957413495566 PMID: 23881908
77. Eckard AR, O’Riordan MA, Rosebush JC, Ruff JH, Chahroudi A, Labbato D, et al. Effects of Vitamin D
Supplementation on Bone Mineral Density and Bone Markers in HIV-Infected Youth. Journal of
acquired immune deficiency syndromes (1999). 2017; 76(5):539–46.
78. Havens PL, Mulligan K, Hazra R, Van Loan MD, Rutledge BN, Bethel J, et al. Increase in fibroblast
growth factor 23 (FGF23) in response to vitamin D3 supplementation in HIV-infected adolescents and
Review: Vit. D supplementation & MSK health outcomes in children, adolescents, & young adults living with HIV
PLOS ONE | https://doi.org/10.1371/journal.pone.0207022 November 15, 2018 23 / 25
young adults on tenofovir-containing combination antiretroviral therapy (cART): Adolescent Trials Net-
work (ATN) study 063. Antiviral therapy. 2012; 17:A7–A8.
79. Crabtree NJ, Arabi A, Bachrach LK, Fewtrell M, El-Hajj Fuleihan G, Kecskemethy HH, et al. Dual-
energy X-ray absorptiometry interpretation and reporting in children and adolescents: the revised
2013 ISCD Pediatric Official Positions. J Clin Densitom. 2014; 17(2):225–42. https://doi.org/10.1016/j.
jocd.2014.01.003 PMID: 24690232
80. Bruininks R. Bruininks-Oseretsky test of motor proficiency. Circle Pines, MN: American Guidance
Service; 1978.
81. Ansemant T, Mahy S, Piroth C, Ornetti P, Ewing S, Guilland JC, et al. Severe hypovitaminosis D corre-
lates with increased inflammatory markers in HIV infected patients. BMC infectious diseases. 2013;
13:7. https://doi.org/10.1186/1471-2334-13-7 PMID: 23295013
82. Foissac F, Meyzer C, Frange P, Chappuy H, Benaboud S, Bouazza N, et al. Determination of optimal
vitamin D3 dosing regimens in HIV-infected paediatric patients using a population pharmacokinetic
approach. British journal of clinical pharmacology. 2014; 78(5):1113–21. https://doi.org/10.1111/bcp.
12433 PMID: 24902982
83. Samarawickrama A, Jose S, Sabin C, Walker-Bone K, Fisher M, Gilleece Y. No association between
vitamin D deficiency and parathyroid hormone, bone density and bone turnover in a large cohort of
HIV-infected men on tenofovir. Journal of the International AIDS Society. 2014; 17(4 Suppl 3):19568.
https://doi.org/10.7448/IAS.17.4.19568 PMID: 25394075
84. Pocaterra D, Carenzi L, Ricci E, Minisci D, Schiavini M, Meraviglia P, et al. Secondary hyperparathy-
roidism in HIV patients: is there any responsibility of highly active antiretroviral therapy? AIDS (Lon-
don, England). 2011; 25(11):1430–3.
85. Lerma E, Molas ME, Montero MM, Guelar A, Gonzalez A, Villar J, et al. Prevalence and Factors Asso-
ciated with Vitamin D Deficiency and Hyperparathyroidism in HIV-Infected Patients Treated in Barce-
lona. Isrn aids. 2012; 2012:485307. https://doi.org/10.5402/2012/485307 PMID: 24052874
86. Havens PL, Kiser JJ, Stephensen CB, Hazra R, Flynn PM, Wilson CM, et al. Association of Higher
Plasma Vitamin D Binding Protein and Lower Free Calcitriol Levels with Tenofovir Disoproxil Fumarate
Use and Plasma and Intracellular Tenofovir Pharmacokinetics: Cause of a Functional Vitamin D Defi-
ciency? Antimicrobial agents and chemotherapy. 2013; 57(11):5619–28. https://doi.org/10.1128/AAC.
01096-13 PMID: 24002093
87. Kwan CK, Eckhardt B, Baghdadi J, Aberg JA. Hyperparathyroidism and Complications Associated
with Vitamin D Deficiency in HIV-Infected Adults in New York City, New York. AIDS research and
human retroviruses. 2012; 28(9):825–32.
88. Eckard AR, Thierry-Palmer M, Silvestrov N, Rosebush JC, O’Riordan MA, Daniels JE, et al. Effects of
cholecalciferol supplementation on serum and urinary vitamin D metabolites and binding protein in
HIV-infected youth. The Journal of steroid biochemistry and molecular biology. 2017; 168:38–48.
https://doi.org/10.1016/j.jsbmb.2017.01.018 PMID: 28161530
89. Liu D, Alvarez-Elias AC, Wile B, Belostotsky V, Filler G. Deviations from the expected relationship
between serum FGF23 and other markers in children with CKD: a cross-sectional study. BMC nephrol-
ogy. 2017; 18(1):204. https://doi.org/10.1186/s12882-017-0623-5 PMID: 28659167
90. Portale AA, Wolf M, Juppner H, Messinger S, Kumar J, Wesseling-Perry K, et al. Disordered FGF23
and mineral metabolism in children with CKD. Clinical journal of the American Society of Nephrology:
CJASN. 2014; 9(2):344–53. https://doi.org/10.2215/CJN.05840513 PMID: 24311704
91. Wesseling-Perry K, Salusky IB. Chronic kidney disease: mineral and bone disorder in children. Semi-
nars in nephrology. 2013; 33(2):169–79. https://doi.org/10.1016/j.semnephrol.2012.12.017 PMID:
23465503
92. Bolland MJ, Grey A, Reid IR. Differences in overlapping meta-analyses of vitamin D supplements and
falls. The Journal of clinical endocrinology and metabolism. 2014; 99(11):4265–72. https://doi.org/10.
1210/jc.2014-2562 PMID: 25093621
93. Reid IR. Vitamin D Effect on Bone Mineral Density and Fractures. Endocrinol Metab Clin North Am.
2017; 46(4):935–45. https://doi.org/10.1016/j.ecl.2017.07.005 PMID: 29080644
94. Wren TA, Kalkwarf HJ, Zemel BS, Lappe JM, Oberfield S, Shepherd JA, et al. Longitudinal tracking of
dual-energy X-ray absorptiometry bone measures over 6 years in children and adolescents: persis-
tence of low bone mass to maturity. The Journal of pediatrics. 2014; 164(6):1280–5.e2. https://doi.org/
10.1016/j.jpeds.2013.12.040 PMID: 24485819
95. Burnham JM, Shults J, Semeao E, Foster B, Zemel BS, Stallings VA, et al. Whole body BMC in pediat-
ric Crohn disease: independent effects of altered growth, maturation, and body composition. J Bone
Miner Res. 2004; 19(12):1961–8. https://doi.org/10.1359/JBMR.040908 PMID: 15537438
96. Hangartner TN, Short DF, Eldar-Geva T, Hirsch HJ, Tiomkin M, Zimran A, et al. Anthropometric adjust-
ments are helpful in the interpretation of BMD and BMC Z-scores of pediatric patients with Prader-Willi
Review: Vit. D supplementation & MSK health outcomes in children, adolescents, & young adults living with HIV
PLOS ONE | https://doi.org/10.1371/journal.pone.0207022 November 15, 2018 24 / 25
syndrome. Osteoporosis international: a journal established as result of cooperation between the
European Foundation for Osteoporosis and the National Osteoporosis Foundation of the USA. 2016;
27(12):3457–64.
97. Kelly A, Schall JI, Stallings VA, Zemel BS. Deficits in bone mineral content in children and adolescents
with cystic fibrosis are related to height deficits. J Clin Densitom. 2008; 11(4):581–9. https://doi.org/10.
1016/j.jocd.2008.07.002 PMID: 18757221
98. Erlandson KM, Allshouse AA, Jankowski CM, MaWhinney S, Kohrt WM, Campbell TB. Functional
impairment is associated with low bone and muscle mass among persons aging with HIV infection.
Journal of acquired immune deficiency syndromes (1999). 2013; 63(2):209–15.
99. Harris SS, Soteriades E, Dawson-Hughes B. Secondary hyperparathyroidism and bone turnover in
elderly blacks and whites. The Journal of clinical endocrinology and metabolism. 2001; 86(8):3801–4.
https://doi.org/10.1210/jcem.86.8.7783 PMID: 11502814
100. Crabtree NJ, Shaw NJ, Bishop NJ, Adams JE, Mughal MZ, Arundel P, et al. Amalgamated Reference
Data for Size-Adjusted Bone Densitometry Measurements in 3598 Children and Young Adults-the
ALPHABET Study. Journal of bone and mineral research: the official journal of the American Society
for Bone and Mineral Research. 2017; 32(1):172–80.
101. Tan DH, Raboud J, Szadkowski L, Szabo E, Hu H, Wong Q, et al. Novel imaging modalities for the
comparison of bone microarchitecture among HIV+ patients with and without fractures: a pilot study.
HIV clinical trials. 2017; 18(1):28–38. https://doi.org/10.1080/15284336.2016.1266074 PMID:
27951753
Review: Vit. D supplementation & MSK health outcomes in children, adolescents, & young adults living with HIV
PLOS ONE | https://doi.org/10.1371/journal.pone.0207022 November 15, 2018 25 / 25
